{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:37:26Z","timestamp":1785893846261,"version":"3.56.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["K08 DK117064"],"award-info":[{"award-number":["K08 DK117064"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["P01 HL 160470-01A1"],"award-info":[{"award-number":["P01 HL 160470-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["17- SFRN33490004"],"award-info":[{"award-number":["17- SFRN33490004"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastrointestinal Endoscopy Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.giec.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:32:10Z","timestamp":1726155130000},"page":"591-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Weight Loss Pharmacotherapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Gabriela","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 O.","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.giec.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib3","first-page":"185","article-title":"Obesity & osteoarthritis","volume":"138","author":"King","year":"2013","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers15020485","article-title":"Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management","volume":"15","author":"Pati","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/oby.2000.32","article-title":"Overweight, obesity, and blood pressure: the effects of modest weight reduction","volume":"8","author":"Mertens","year":"2000","journal-title":"Obes Res"},{"issue":"22","key":"10.1016\/j.giec.2024.06.006_bib6","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1001\/jama.2022.21908","article-title":"The challenge of defining the optimal lifestyle weight loss intervention for real-world settings","volume":"328","author":"Wing","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.giec.2024.06.006_bib7","doi-asserted-by":"crossref","first-page":"g2646","DOI":"10.1136\/bmj.g2646","article-title":"Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials","volume":"348","author":"Dombrowski","year":"2014","journal-title":"BMJ"},{"issue":"10031","key":"10.1016\/j.giec.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11938-023-00420-6","article-title":"Endobariatrics: a still underutilized weight loss tool","volume":"21","author":"Dave","year":"2023","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ajg.2016.530","article-title":"The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis","volume":"112","author":"Popov","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.giec.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"1043595","DOI":"10.3389\/fendo.2022.1043595","article-title":"Pharmacologic management of weight regain following bariatric surgery","volume":"13","author":"Lucas","year":"2023","journal-title":"Front Endocrinol"},{"issue":"9123","key":"10.1016\/j.giec.2024.06.006_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.giec.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/2230-8210.81938","article-title":"Evaluation of efficacy and safety of orlistat in obese patients","volume":"15","author":"Jain","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.giec.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1381\/096089202321144685","article-title":"Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band","volume":"12","author":"Zoss","year":"2002","journal-title":"Obes Surg"},{"issue":"1","key":"10.1016\/j.giec.2024.06.006_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","article-title":"Orlistat-associated adverse effects and drug interactions: a critical review","volume":"31","author":"Filippatos","year":"2008","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"10382","key":"10.1016\/j.giec.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00171-X","article-title":"Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance","volume":"42","author":"Herrero","year":"2002","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.giec.2024.06.006_bib21","first-page":"446","article-title":"Phentermine\/topiramate extended-release capsules (qsymia) for weight loss","volume":"38","author":"Lonneman","year":"2013","journal-title":"P\u00a0T"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1345\/aph.1R501","article-title":"Phentermine\/topiramate for the treatment of obesity","volume":"47","author":"Smith","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11695-015-1979-x","article-title":"Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review","volume":"26","author":"Schwartz","year":"2016","journal-title":"Obes Surg"},{"issue":"7","key":"10.1016\/j.giec.2024.06.006_bib25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.soard.2019.04.017","article-title":"Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50\u00a0kg\/m2 or more","volume":"15","author":"Ard","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.soard.2016.10.018","article-title":"The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study","volume":"13","author":"Stanford","year":"2017","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1381\/0960892041590926","article-title":"Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight","volume":"14","author":"Zilberstein","year":"2004","journal-title":"Obes Surg"},{"issue":"12","key":"10.1016\/j.giec.2024.06.006_bib28","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jama.2015.1617","article-title":"Naltrexone extended-release plus bupropion extended-release for treatment of obesity","volume":"313","author":"Yanovski","year":"2015","journal-title":"JAMA"},{"issue":"9741","key":"10.1016\/j.giec.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/fca.15.79","article-title":"Naltrexone\/bupropion for the treatment of obesity and obesity with type 2 diabetes","volume":"12","author":"Apovian","year":"2016","journal-title":"Future Cardiol"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1319-3767.203362","article-title":"Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?","volume":"23","author":"Mosli","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.giec.2024.06.006_bib32","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S58459","article-title":"Liraglutide and obesity: a review of the data so far","volume":"9","author":"Ladenheim","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.giec.2024.06.006_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.giec.2024.06.006_bib34","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes"},{"issue":"Suppl 3","key":"10.1016\/j.giec.2024.06.006_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","article-title":"The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1590\/S0100-69912013000300005","article-title":"Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery","volume":"40","author":"Pajecki","year":"2013","journal-title":"Rev Col Bras Cir"},{"issue":"7, Supplement","key":"10.1016\/j.giec.2024.06.006_bib38","first-page":"S157","article-title":"A5163 - use of liraglutide for weight loss in patients with prior bariatric surgery","volume":"12","author":"Creange","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"10","key":"10.1016\/j.giec.2024.06.006_bib39","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.soard.2016.02.013","article-title":"Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"7","key":"10.1016\/j.giec.2024.06.006_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.giec.2024.06.006_bib41","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s11695-018-3393-7","article-title":"Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery","volume":"28","author":"Rye","year":"2018","journal-title":"Obes Surg"},{"issue":"1","key":"10.1016\/j.giec.2024.06.006_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.orcp.2016.10.078","article-title":"Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE obesity and prediabetes","volume":"13","author":"Proietto","year":"2019","journal-title":"Obes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.giec.2024.06.006_bib43","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0\u00a0mg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib44","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.gie.2020.10.016","article-title":"Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss","volume":"93","author":"Badurdeen","year":"2021","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"10.1016\/j.giec.2024.06.006_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib47","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4\u00a0mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.giec.2024.06.006_bib48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10278","key":"10.1016\/j.giec.2024.06.006_bib49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.giec.2024.06.006_bib50","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.giec.2024.06.006_bib51","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"issue":"9","key":"10.1016\/j.giec.2024.06.006_bib52","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A\u00a0pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.giec.2024.06.006_bib54","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"10192","key":"10.1016\/j.giec.2024.06.006_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib56","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.giec.2024.06.006_bib57","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov Today Technol"},{"issue":"11","key":"10.1016\/j.giec.2024.06.006_bib58","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther Deliv"},{"issue":"7","key":"10.1016\/j.giec.2024.06.006_bib59","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s13300-021-01078-y","article-title":"Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation","volume":"12","author":"B\u00e6kdal","year":"2021","journal-title":"Diabetes Ther"},{"issue":"10","key":"10.1016\/j.giec.2024.06.006_bib60","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1007\/s11695-022-06211-9","article-title":"The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis","volume":"32","author":"Lautenbach","year":"2022","journal-title":"Obes Surg"},{"issue":"1","key":"10.1016\/j.giec.2024.06.006_bib61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1\u20132","key":"10.1016\/j.giec.2024.06.006_bib62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J\u00a0Diabetes Investig"},{"issue":"10295","key":"10.1016\/j.giec.2024.06.006_bib63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2021 Jul 17;398(10296):212]","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.giec.2024.06.006_bib64","doi-asserted-by":"crossref","first-page":"bvad016","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J\u00a0Endocr Soc"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.giec.2024.06.006_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.giec.2024.06.006_bib67","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","article-title":"Bariatric surgery and long-term durability of weight loss","volume":"151","author":"Maciejewski","year":"2016","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.giec.2024.06.006_bib68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A\u00a0new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.giec.2024.06.006_bib70","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral glp-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib71","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.gie.2018.12.012","article-title":"Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients","volume":"89","author":"Alqahtani","year":"2019","journal-title":"Gastrointest Endosc"},{"issue":"6","key":"10.1016\/j.giec.2024.06.006_bib72","doi-asserted-by":"crossref","first-page":"AB6","DOI":"10.1016\/j.gie.2021.03.083","article-title":"\u201cSemaglutide in association to endoscopic sleeve gastroplasty: taking endoscopic batriatric procedures outcomes to the next level\u201d","volume":"93","author":"Carolina Hoff","year":"2021","journal-title":"Gastrointest Endosc"},{"issue":"7","key":"10.1016\/j.giec.2024.06.006_bib73","doi-asserted-by":"crossref","first-page":"e0289006","DOI":"10.1371\/journal.pone.0289006","article-title":"Effectiveness of a preoperative orlistat-based weight management plan and its impact on the results of oneanastomosis gastric bypass: A retrospective study","volume":"18","author":"Lo","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.giec.2024.06.006_bib74","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.socscimed.2015.12.024","article-title":"\"When the honeymoon is over, the real work begins:\" Gastric bypass patients' weight loss trajectories and dietary change experiences","volume":"151","author":"Lynch","year":"2016","journal-title":"Soc Sci Med"}],"container-title":["Gastrointestinal Endoscopy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105251572400059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105251572400059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T19:19:38Z","timestamp":1726773578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105251572400059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S105251572400059X"],"URL":"https:\/\/doi.org\/10.1016\/j.giec.2024.06.006","relation":{},"ISSN":["1052-5157"],"issn-type":[{"value":"1052-5157","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight Loss Pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Gastrointestinal Endoscopy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.giec.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}